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Natural killer T-cell lymphoma (NKTL) is a dis-
tinct clinicopathologic entity with CD16+, CD56+,
CD57+, CD3e+, and surface CD3- immunopheno-
type, absence of T-cell receptor gene rearrange-
ment, association to the Epstein-Barr virus (EBV),
and prevalence in certain regions of Asia and Cen-
tral America.1–6 While the tumor preferential site
is the nasopharyngeal region, it also arises in
the skin, subcutis, gastrointestinal tract, spleen,
testis, and kidney. However the term of “nasal-
type” NKTL is recommended even for extranasal
tumors.2;4–6 Other names used includes poly-
morphic reticulosis, midline lethal granuloma,
lymphomatoid granulomatosis, and angiocentric* Corresponding author. Tel.: +852-2632-1136; fax: +852-2649-
7286.
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doi:10.1016/j.ooe.2003.11.005lymphoma, all carrying a dismal prognosis.1;3;5
Staging is an important determinant to survival,
but the tumor grading remains unproven for prog-
nosis.1;3 We describe a case of primary gingival
NKTL, representing the so far longest survival re-
ported, despite relapses.1–5Case report
A 19-year-old woman presented in 1988 with
bleeding gum, due to a 0.7 cm ulcer opposite to the
right lower pre-molar. The biopsy revealed an
infiltration of small neoplastic lymphoid cells
associated with necrosis, for which the diagnosis of
T-cell non-Hodgkin lymphoma was reported. The
clinical stage IE was established based on the Ann
Arbor system, which included bone marrow biopsy,
bipedal lymphangiogram, and computed tomogra-
phy of the abdomen and pelvis.1 Surgical excisionved.
Figure 1 Small neoplastic lymphoid cells with pleo-
morphic nuclei, distinct nucleoli, and active mitosis
(Hematoxylin and Eosin, ·400).
Primary oral nasal-type NK/T lymphoma 37was performed without additional therapy, and 11
months post-operatively a left nasal cavity recur-
rent tumor was confirmed by biopsy (Fig. 1). The
tumor cells were immunoreactive to CD45RB,
cytoplasmic polyclonal CD3 (epsilon chain),
CD45RO, CD56 (neural cell adhesion molecule (Fig.
2a), T-cell intracellular antigen-1 (Fig. 2b), but notFigure 2 Immunoreactivity of neoplastic lymphoid cells: (ato CD20, CD30 (Ki-1) and ALK-1, indicative of a NK/
T-cell lineage.1;2 In-situ hybridization for EBV-en-
coded small RNAs (EBERs) revealed EBERs in both
gingival and nasal tumors (Fig. 2c). Chemotherapy
combining prednisolone, methotrexate, adriamy-
cin, cyclophosphamide and etoposide (ProMACE)
given in three cycles achieved a complete re-
sponse. She did well until recently, after 14 years
when presented with a right nasal tumor. The
neoplastic lymphoid cells on biopsy were similar to
those in previous gingival and nasal lesions, except
for the slightly larger nuclei, but the immunophe-
notype was identical and EBERs were demonstrated
confirming a relapse. Routine blood tests and bone
marrow were unremarkable. The patient was given
three of the scheduled six cycles of high dose
methotrexate, bleomycin, Adriamycin, cyclophos-
phamide, vincristine (Oncovin) and dexamethasone
(mBACOD), to be followed by a high dose BEAM
chemotherapy with autologous bone marrow
transplantation, and local radiotherapy for con-
solidation. After three months of therapy, two
biopsies revealed persistent tumor, and a treat-
ment response has yet to be seen.) CD56 stain, (b) TIA-1 stain and (c) EBER stain (all250).
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Nasal-type NKTL is rare distinct clinicopatho-
logic entity with a natural killer immunopheno-
type, lacking T-cell receptor gene rearrangement,
and demonstrable EBV mRNAs in the majority of
cases.1–3 The nuclear size constitutes the basis for
tumor grading, though its prognostic value remains
unproven, due both to the rarity and high mortality
of this tumor.1;3
This example illustrates that even after a long
period of remission, extranasal NKTL interestingly
may relapse in the nasopharynx, suggesting the
notion of tumor “homing” to the nasal region.2;3;5
EBV antigens or mRNAs have been demonstrated in
most primary tumors, though the role of EBV in the
carcinogenesis of NKTL remains controversial.1;3;5;6
Moreover, the suggestion that EBV may accelerate
the clinical course is not supported by our patient
who survived 15 years with a consistently EBERs
expressing tumor.
NKTL usually showed a poor outcome with a
survival of 3–24 months, which correlated with the
tumor staging.1–4 To our best knowledge, this pa-
tient represents so far the longest survival from
NKTL, and it seems worthwhile discussing some of
her features. NKTL mostly affects male at the
mean age 45, and thus this case may suggest the
favorable influence of gender and age.1–3;5
Relapsing tumor cells tend to be larger, in contrast
to our observation. The tumor confinement within
the upper aerodigestive region is reminiscent of
the “homing” concept seen in low-grade mucosal-
associated lymphomas, lacking tendency to dis-
seminate, a notion valid to this NKTL patient with
prolonged survival.3From this example, surgery needs to be com-
plemented with aggressive chemotherapy in NKTL.
Currently, combined high dose multi-drug chemo-
therapy and radiotherapy appear ineffective in
most cases of nasal-type NKTL. Re-induction che-
motherapy followed by intensive chemotherapy
and radiotherapy with autologous bone marrow
infusion as rescue may be attempted to cure pa-
tients with relapse, but arguably does our patient
require such an extreme therapy? New strategies
including immunotherapy targeting EBV antigens
may be considered in patients with prolonged sur-
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